MedTrace Logo

Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy

NCT00929565 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2012-04-09

No results posted yet for this study

Summary

Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway.

The investigators plan to measure these factors prior to and after bronchoscopy.

Conditions

  • Hemoptysis

Sponsors & Collaborators

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Jijo John, MD · University of Oklahoma

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-06-30
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00929565 on ClinicalTrials.gov